SARS‐CoV‐2 show no infectivity at later stages in a prolonged COVID‐19 patient despite positivity in RNA testing

Inpatient coronavirus disease 2019 (COVID‐19) cases present enormous costs to patients and health systems in the United States. Many hospitalized patients may continue testing COVID‐19 positive even after the resolution of symptoms. Thus, a pressing concern for clinicians is the safety of discharging these asymptomatic patients if they have any remaining infectivity. This case report explores the viral viability in a patient with persistent COVID‐19 over the course of a 2‐month hospitalization. Positive nasopharyngeal swab samples were collected and isolated in the laboratory and analyzed by quantitative reverse‐transcription polymerase chain reactions (qRT‐PCR), and serology was tested for neutralizing antibodies throughout the hospitalization period. The patient experienced waning symptoms by hospital day 40 and had no viable virus growth by hospital day 41, suggesting no risk of infectivity, despite positive RT‐PCR results which prolonged his hospital stay. Notably, this case showed infectivity for at least 24 days after disease onset, which is longer than the discontinuation of transmission‐based precautions recommended by the Center for Disease Control and Prevention. Thus, our findings suggest that the timeline for discontinuing transmission‐based precautions may need to be extended for patients with severe and prolonged COVID‐19 disease. Additional large‐scale studies are needed to draw definitive conclusions on the appropriate clinical management for these patients.

[1]  J. McElroy,et al.  SARS-CoV-2 show no infectivity at later stages in a prolonged COVID-19 patient despite positivity in RNA testing , 2021, medRxiv.

[2]  R. Jin,et al.  Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China , 2021, Frontiers in Immunology.

[3]  Prabhat K. Singh,et al.  Persistent positivity of SARS-CoV-2 nucleic acid in asymptomatic healthcare worker: infective virion or inactive nucleic acid? , 2021, BMJ Case Reports.

[4]  V. Calvez,et al.  Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers , 2021, Nature Communications.

[5]  M. M. van der Eerden,et al.  Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) , 2021, Nature communications.

[6]  Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity , 2020, Cell death discovery.

[7]  J. Wapner Covid-19: Medical expenses leave many Americans deep in debt , 2020, BMJ.

[8]  L. Parida,et al.  Variant analysis of SARS-CoV-2 genomes , 2020, Bulletin of the World Health Organization.

[9]  N. Jewell,et al.  Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study , 2020, BMJ.

[10]  P. V. Van Caeseele,et al.  Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples , 2020, Clinical Infectious Diseases.

[11]  A. Broom,et al.  SARS-CoV-2: The viral shedding vs infectivity dilemma , 2020, Infection, Disease & Health.

[12]  T. Lv,et al.  Prolonged SARS‐CoV‐2 RNA shedding: Not a rare phenomenon , 2020, Journal of medical virology.

[13]  M. A. O. Ignacio,et al.  How to cite this article , 2016 .

[14]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .